India-based Lupin is holding discussions with Sanofi’s generic arm, Zentiva, to acquire Pulmojet, its dry powder inhalation brand, according to CNBC TV18 sources.
Lupin hopes the deal will boost its global inhalation therapy business, as it looks to grow in the U.S. market. Lupin says it is developing nine compounds in the inhalation segment.
In recent news for Lupin, the drugmaker has received U.S. FDa approval to market a generic version of Braintree Laboratories’s Suprep Bowel Prep Kit and launched scalp treatment and a dermatology drug in the U.S. The company has also entered into a marketing agreement in Japan to exclusively distribute and promote extended-release tablets of schizophrenia drug.